The Prognostic Significance of Multiple Station N2 in Patients with Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer

다국어 초록 (Multilingual Abstract)

Mediastinal (N2) lymph node involvement is heterogenous with huge variation in

the extent and grouped together under stage IIIA. However, they showed a different

survival even in the same stage. We tried to determine the prognostic implication

of the multiple station N2 lymph node metastasis in stage IIIA N2 non-small cell

lung cancer (NSCLC). The survival of stage IIIA N2 was analyzed according to the

number of N2 station and their survival was compared with that of stage IIIB. In

stage IIIA N2 NSCLC, multivariate analysis indicated that multiple station N2 was

one of the independent prognostic factors for poor survival. The 5-yr survival of

multiple station N2 IIIA (20.4%) was lower than that of single station N2 IIIA (33.8%)

significantly (p=0.016). but when it was compared with that of stage IIIB (15.5%),

there was no difference. Therefore, we suggest that multiple station N2 should be

considered similar to stage IIIB disease with regard to predicting survival and accordingly

should receive a new position in the TNM staging system.

참고문헌 (Reference)

1 Martini N, "The role of surgery in N2 lung cancer" 67 : 1037-1049, 1987

2 Naruke T, "The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis" 46 : 603-610, 1988

3 Andre F, "Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications" 18 : 2981-2989, 2000

4 Osaki T, "Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer" 43 : 151-157, 2004

5 Mountain CF, "Surgery for stage IIIa-N2 non-small cell lung cancer" 73 : 2589-2598, 1994

6 Riquet M, "Skip mediastinal lymph node metastasis and lung cancer:a particular N2 subgroup with a better prognosis" 79 : 225-233, 2005

7 Pearson FG, "Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung" 83 : 1-11, 1982

8 Mountain CF, "Revisions in the international system for staging lung cancer" 111 : 1710-1717, 1997

9 Inoue M, "Results of surgical intervention for p-stage IIIA (N2) non small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe" 127 : 1100-1106, 2004

10 Mountain CF, "Regional lymph node classification for lung cancer staging" 111 : 1718-1723, 1997

11 Grunenwald D, "Re: Stage IIIA category of non-small cell lung cancer: a new proposal" 89 : 88-89, 1997

12 Naruke T, "Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience" 71 : 1759-1764, 2001

13 Watanabe Y, "Mediastinal nodal involvement and prognosis of non-small cell lung cancer" 100 : 422-428, 1991

14 Murray JG, "Mediastinal lymph node size in an Asian population" 68 : 348-350, 1995

15 Keller SM, "Mediastinal lymph node dissection improves survival in patients with stage II and IIIA non-small cell lung cancer. Eastern Cooperative Oncology Group" 70 : 358-366, 2000

16 Vansteenkiste JF, "Lerut TE, Demedts MG. Clinical prognostic factors in surgically treated stage IIIA-N2 nonsmall cell lung cancer: analysis of the literature" 19 : 3-13, 1998

17 Ichinose Y, "Japanese Clinical Oncology Group. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station" 122 : 803-808, 2001

18 Arita T, "Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography and nodal specimen" 110 : 1004-1008, 1996

19 Winton T, "Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs observation in resected non-smallcell lung cancer" 352 : 2589-2597, 2005

20 Ruckdeschel JC, "Combined modality therapy of non-small cell lung cancer" 24 : 429-439, 1997

21 Douillard J, "ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients: Final results after 70-month median follow-up, On behalf of the Adjuvant Navelbine International Trialists Association" 23 : 624 -, 2005